Webcast ImageWebcast
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference  (Replay)
03/21/17 at 3:55 p.m. ET
BioTime, Inc. at Oppenheimer 27th Annual Healthcare Conference
Tuesday, March 21, 2017 3:55 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
March 21, 2017OncoCyte Submits Application for CLIA Certification of its Laboratory
Achieving Certification is Key Step for Planned Commercial Launch in the Second Half of 2017 ALAMEDA, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, has submitted its application for CLIA certification of its laboratory, the next step towards its objective of launching the Company’s first commercial product, a lung cancer diagnostic test, in the second half of 2017.  ... 
Printer Friendly Version
March 21, 2017Update on Full Six-Patient Cohort Confirms Patients with Complete Paralysis Can Experience Meaningful Recovery of Function by Six Months Following AST-OPC1 Treatment
-Newly reported data on sixth and final patient in cohort further confirms previously announced improvements in hand and arm function following dosing- FREMONT, Calif., March 21, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, reported that including the sixth and final patient in the AIS-A 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical trial has further confirmed previousl... 
Printer Friendly Version
March 07, 2017Asterias Biotherapeutics to Report Fourth Quarter and Full Year Results on March 28, 2017
FREMONT, Calif., March 7, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release fourth quarter and full year 2016 financial and operational results on Tuesday, March 28, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast on March 28, 2017 at 4:30 p.m. Eastern / 1:30 p.m. For both "listen-only" participants and those par... 
Printer Friendly Version
March 06, 2017OncoCyte Reports Successful Results of Lung Cancer Diagnostic Test Study; Targets 2017 Product Launch to Address $4 Billion-plus Market
Data from the Study Exceed Levels Believed Necessary for a Commercially Successful Test Conference Call Scheduled for Today at 4:30 PM ET ALAMEDA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests to aid in the early detection of cancer, today reported the successful completion of a critical step in the development of its lung cancer diagnostic test. While the key performance metrics of its diagnostic cannot... 
Printer Friendly Version
March 01, 2017OncoCyte Corporation to Present at Cowen and Company 37th Annual Health Care Conference
ALAMEDA, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will begin at 9:20 a.m. ET on Wednesday, March 8th, 2017 at the Boston Marriott Copley Place. Plea... 
Printer Friendly Version
February 27, 2017OncoCyte Corporation Reports Fourth Quarter and Full Year 2016 Financial Results
Enters into New Credit Facility with Silicon Valley Bank Conference Call Scheduled for Monday, March 6, 2017 at 4:30 PM ET ALAMEDA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive, ”liquid biopsy” tests to aid in the early detection of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2016. OncoCyte also reported that it has entered into a secured loan agreement with Silicon Val... 
Printer Friendly Version
February 21, 2017OncoCyte Receives $2 Million in Proceeds from Early Exercise of Warrants
Completes Sample Collection and Processing for the 300-Patient Study of its Lung Cancer Diagnostic Test ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants.  Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued durin... 
Printer Friendly Version
February 13, 2017OncoCyte Corporation to Present at the 19th Annual BIO CEO & Investor Conference and the 2017 Disruptive Growth & Healthcare Conference
ALAMEDA, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14th, at 10:30 a.m. ET, where OncoCyte is also being recognized and honored as the Buzz of BIO winner in the “diagnostics ... 
Printer Friendly Version
February 03, 2017Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position
- Warrant extension follows positive recent update on further motor function improvements observed in SCiStar study patients dosed with AST-OPC1 - - Cash position significantly improved from the same time last year - FREMONT, Calif., Feb. 3, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the company is extending the expiration date of certain warrants. The decision to ex... 
Printer Friendly Version
January 27, 2017OncoCyte Wins Buzz of BIO for the 2017 BIO CEO & Investor Conference
ALAMEDA, Calif., Jan. 27, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that the Biotechnology Innovation Organization (BIO) has recognized OncoCyte Corporation as the Buzz of BIO winner in the “diagnostics and beyond category” for the 2017 BIO CEO & Investor Conference taking place February 13–14 at the Waldorf Astoria in New York. Nominated and selected by an online vote, contest winners are... 
Printer Friendly Version
January 24, 2017Asterias Announces Additional Motor Function Improvement at 6-months and 9-months Following Treatment with AST-OPC1 in Patients with Complete Cervical Spinal Cord Injuries
-Management to discuss results on conference call today at 5:00 p.m. Eastern / 2:00 p.m. Pacific- -SCiStar lead investigator Richard Fessler, MD, and John Steeves, Ph.D., Co-Chair of the Spinal Cord Outcomes Partnership Endeavor (SCOPE), will join Asterias management on the call- FREMONT, Calif., Jan. 24, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced positive efficacy... 
Printer Friendly Version
January 24, 2017OncoCyte to Present Interim Data from Its Lung Cancer Diagnostic Test Study at the American Thoracic Society Conference May 22, 2017
ALAMEDA, Calif., Jan. 24, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its abstract on interim data from the Company’s lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C.  The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicin... 
Printer Friendly Version
January 04, 2017OncoCyte Provides Updated Timelines on Diagnostic Test Development and Commercialization Plans
Breast Cancer Test Development Three to Six Months Ahead of Schedule; Commercial Launch Possible in Mid to Late 2018 Lung Cancer Test Development Two to Three Months Behind Schedule; Commercial Launch Planned for Second Half of 2017 ALAMEDA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today provided an update on the development of its product portfolio that c... 
Printer Friendly Version